Boston Scientific Corp (BSX) stock
Close on Nov 12, 2026Market cap $64.06BP/E 18.7Yield –
Boston Scientific Corp grew revenue 8.9% to $21.07B over the twelve months to Sep 30, 2026. Operating income rose 13.5% to $3.93B, moving the operating margin from 17.9% to 18.7%. Free cash flow was $3.33B, down 12.9% from a year earlier. At the latest close the market valued the company at $64.06B, 18.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $64.06B
- P/E ratio
- 18.7
- Price to sales
- 3.04
- Price to book
- 2.50
- Dividend yield
- –
- Free cash flow yield
- 5.20%
Fundamentals
- Revenue
- $21.07B
- EPS, diluted
- $2.36
- Free cash flow
- $3.33B
- Book value per share
- $17.65
- Diluted shares
- 1.45B
Trading
- Next earnings
- Feb 3, 2027 (estimated, before the open)
- Previous close
- $45.13
- Open
- $45.40
- Day's range
- $43.79 – $45.60
- Volume
- 11,505,060
- Average volume (20 days)
- 20,222,536
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.78
- 52-week range
- $39.57 – $105.65
- RSI (14 days)
- 49.9
- Volatility (1 year)
- 40.1%
- Relative volume
- 0.59×
- WACC
- 8.1%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BSX | S&P 500 | Difference | BSX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.8% | -2.7% | +3.5 pts | ||
| 3 months | -14.0% | -1.7% | −12.3 pts | ||
| Year to date | -53.6% | +11.9% | −65.5 pts | ||
| 1 year | -57.6% | +12.0% | −69.5 pts | ||
| 3 years | -14.3% | +78.2% | −92.5 pts | -5.0% | +21.2% |
| 5 years | +5.1% | +73.2% | −68.2 pts | +1.0% | +11.6% |
| 10 years | +105.6% | +309.6% | −204.1 pts | +7.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Boston Scientific filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating OfficerNews
- Results
- News
- News
- Results
About Boston Scientific
Surgical & Medical Instruments & Apparatus
Boston Scientific Corporation develops, manufactures, and markets medical devices for less-invasive diagnostic and therapeutic procedures across diverse specialties. The company conducts business through two reportable segments: MedSurg and Cardiovascular. Its MedSurg segment supplies minimally invasive equipment for gastrointestinal, urological, and chronic neurological conditions, including single-use scopes, stent systems, laser platforms, and spinal cord stimulators. The Cardiovascular segment provides vascular guidance catheters, drug-eluting therapies, electrophysiology ablation solutions, structural heart closure devices, implantable cardiac rhythm devices, and embolization products. Boston Scientific markets these technologies primarily to hospitals, outpatient clinics, healthcare providers, and group purchasing organizations.
Company profile, executives and historyBoston Scientific stock: common questions
What is Boston Scientific's stock price?
BSX closed at $44.20 on Nov 12, 2026, down 2.06% on the day. Over the past 52 weeks it traded between $39.57 and $105.65.
What is Boston Scientific's market cap?
Boston Scientific was worth $64.06B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BSX's P/E ratio?
BSX trades at 18.7 times earnings, based on diluted earnings per share of $2.36 over the twelve months to Sep 30, 2026.
How much revenue does Boston Scientific make?
Boston Scientific reported revenue of $21.07B for the twelve months to Sep 30, 2026, up 8.9% from a year earlier.
Does Boston Scientific pay a dividend?
No. Boston Scientific has not paid a cash dividend over the last twelve months.
When does Boston Scientific report earnings next?
Boston Scientific is expected to report Q4 FY2026 results on Feb 3, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BSX stock performed over the past year?
Including dividends, BSX returned -57.6% over the past year, against +12.0% for the S&P 500.
How many BSX shares are sold short?
35M shares were sold short at the latest FINRA report, 2.43% of the float, or 1.6 days of average trading volume.
Who are Boston Scientific's competitors?
Companies most similar to Boston Scientific by business, industry and size include BDX, BAX, SYK, MDLN, SOLV.
See a number that looks wrong?